Faber: Valeant to make $45B+ hostile bid for Allergan
Yesterday, 05:53 PM ET · VRX
David Faber reports Valeant (VRX) will make a $45B+ hostile bid for Allergan (AGN), of which 1/3 will be financed with cash. He expects an announcement tomorrow.
After factoring a 6% gain in regular trading a 19.7% AH gain, Allergan is currently worth $50.9B. Valeant is worth $46.4B, after accounting for a 3.2% gain in regular trading and a 10.3% AH gain.
Valeant and Bill Ackman’s Pershing Square Capital have each filed 13Ds (I, II) stating Pershing Square now has a 9.7% stake in Allergan.
Valeant says it expects to propose a merger with a ~$15B cash component, and that it’s contributing $75.9M in working capital to an entity (known as PS Fund 1) to be used by Valeant and Pershing to pursue their bid.
Faber: “So Ackman can buy $3b in [Allergan] stock, which he will sell to [Valeant] for a lot more if it succeeds in an offer Ackman knew was coming.”
var isMC=true; var adSize=’320×50′; var ord = Math.floor(Math.random()*10e12); var seekingalpha_ad_src=’http://ad.doubleclick.net/N6001/adj/sek.mobile/app;sz=320×50,320×250;x=x;tile=1;d=mobile;t=app;mcid=true;mcid=1683703;s=VRX;s=AGN;’+dart_my_vocation_and_profiles()+’ord=’+ord+’;dev=ip?’; document.write(”);
April 22nd, 2014 at 6:54 am
Faber: Valeant to make $45B+ hostile bid for Allergan
Yesterday, 05:53 PM ET · VRX